New CAR T-Cell therapy targets Hard-to-Treat multiple myeloma in early trial
NCT ID NCT07510100
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new treatment called Equecabtagene autoleucel for people with multiple myeloma that has returned or stopped responding to at least three prior therapies. The treatment uses a patient's own immune cells, modified to attack a protein called BCMA on myeloma cells. The study will enroll 17 participants to check for side effects and see how well the therapy works.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institute of Science Tokyo Hospital
Bunkyo-ku, Tokyo, 113-8519, Japan
-
Japanese Red Cross Medical Center
Shibuya-ku, Tokyo, 150-8935, Japan
-
Nihon University Itabashi Hospital
Itabashi-ku, Tokyo, 173-8610, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered immune cells take aim at Hard-to-Treat myeloma
- Can engineered immune cells outsmart Treatment-Resistant myeloma?
- Can a lower dose of a myeloma drug keep the disease in check with fewer side effects?
- A pre-treatment pill may supercharge cancer-fighting immune cells
- New antibody combo aims to stall multiple Myeloma's return
- Real-World data may reveal best Second-Line therapy for multiple myeloma